$-PR^cR^d$, $-P(O)R^cR^d$, $-P(O)_2R^cR^d$, $-P(O)NR^cR^d$, $-P(O)_2NR^cR^d$, $-P(O)OR^c$, $-P(O)_2OR^c$, -CN, or $-NO_2$;


[022] each R^a, R^b, R^c, R^d, R^e, and R^f is independently selected from the group consisting of H, deuterium, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, C_1-C_6 alkylene-C_6-C_{10} aryl, and 5- to 10-membered heteroaryl;

[023] m is 0, 1, 2, 3, or 4;

[024] n is 0, 1, 2, 3, or 4, and

[025] o is 0, 1, 2, or 3.

[026] In another example, the disclosure relates to a compound of the formula Ia, or a pharmaceutically acceptable salt thereof,



Ia

[027] wherein

[028] A is a ring selected from 5- to 10-membered heteroarylene or C_6-C_{10} arylene;

[029] X is $C(R^2)$ or N;

[030] X^1 is $C(R^3)$ or N;

[031] X^2 is $C(R^4)$ or N;

[032] Y is O, $N(R^5)C(O)$, $C(O)N(R^5)$, $N(R^6)$, $N(R^5)S(O)$, $S(O)N(R^5)$, $N(R^5)S(O)_2$, $S(O)_2N(R^5)$, S, S(O), $S(O)_2$, or Y is absent;

[033] each Y^1 is independently O, $C(O)N(R^7)$, $N(R^7)C(O)$, $N(R^8)$, $N(R^7)S(O)$, $S(O)N(R^7)$, $N(R^7)S(O)_2$, $S(O)_2N(R^7)$, S, S(O), $S(O)_2$, or absent;

[034] Y^2 is O, $C(O)N(R^9)$, $N(R^9)C(O)$, $N(R^{10})$, $N(R^9)S(O)$, $S(O)N(R^9)$, $N(R^9)S(O)_2$, $S(O)_2N(R^9)$, S, S(O), $S(O)_2$, or Y^2 is absent;

[035] each L is independently a C_1-C_6 alkylene, wherein each hydrogen atom in C_1-C_6 alkylene is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, 5-


to 7-membered heterocycloalkyl, C_6-C_{10} aryl, C_1-C_6 alkylene-C_6-C_{10} aryl, 5- to 10-membered heteroaryl, or C_1-C_6 alkylene-5- to 10-membered heteroaryl is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, -OH, -OC_1-C_6 alkyl, -OC(O)-(H or C_1-C_6 alkyl), -OC(O)N(H or C_1-C_6 alkyl)$_2$, -OC(O)N(C_2-C_6 alkylene), -OS(O)-(H or C_1-C_6 alkyl), -OS(O)$_2$-(H or C_1-C_6 alkyl), -OS(O)N(H or C_1-C_6 alkyl)$_2$, -OS(O)N(C_2-C_6 alkylene), -OS(O)$_2$N(H or C_1-C_6 alkyl)$_2$, -OS(O)$_2$N(C_2-C_6 alkylene), -S(H or C_1-C_6 alkyl), -S(O)(H or C_1-C_6 alkyl), -S(O)$_2$(H or C_1-C_6 alkyl), -S(O)N(H or C_1-C_6 alkyl)$_2$, -S(O)N(C_2-C_6 alkylene), -S(O)$_2$N(H or C_1-C_6 alkyl)$_2$, -S(O)$_2$N(C_2-C_6 alkylene), -N(H or C_1-C_6 alkyl)$_2$, -N(C_2-C_6 alkylene), -N(H or C_1-C_6 alkyl)C(O)-(H or C_1-C_6 alkyl), -N(H or C_1-C_6 alkyl)C(O)O(H or C_1-C_6 alkyl), -N(H or C_1-C_6 alkyl)C(O)N(H or C_1-C_6 alkyl)$_2$, -N(H or C_1-C_6 alkyl)C(O)N(C_2-C_6 alkylene), -N(H or C_1-C_6 alkyl)S(O)-(H or C_1-C_6 alkyl), -N(H or C_1-C_6 alkyl)S(O)$_2$(H or C_1-C_6 alkyl), -N(H or C_1-C_6 alkyl)S(O)N(H or C_1-C_6 alkyl)$_2$, -N(H or C_1-C_6 alkyl)S(O)N(C_2-C_6 alkylene), -N(H or C_1-C_6 alkyl)S(O)$_2$N(H or C_1-C_6 alkyl)$_2$, -N(H or C_1-C_6 alkyl)S(O)$_2$N(C_2-C_6 alkylene), -C(O)-(H or C_1-C_6 alkyl), -C(O)O(H or C_1-C_6 alkyl), -C(O)N(C_2-C_6 alkylene), -P(H or C_1-C_6 alkyl)$_2$, -P(C_2-C_6 alkylene), -P(O)(H or C_1-C_6 alkyl)$_2$, -P(O)(C_2-C_6 alkylene), -P(O)$_2$(H or C_1-C_6 alkyl)$_2$, -P(O)$_2$(C_2-C_6 alkylene), -P(O)N(H or C_1-C_6 alkyl)$_2$, -P(O)N(C_2-C_6 alkylene), -P(O)$_2$N(H or C_1-C_6 alkyl)$_2$, -P(O)$_2$N(C_2-C_6 alkylene), -P(O)O(H or C_1-C_6 alkyl), -P(O)$_2$O(H or C_1-C_6 alkyl), -CN, or -NO_2;

[041] m is 0, 1, 2, 3, or 4;

[042] n is 0, 1, 2, 3, or 4; and

[043] o is 0, 1, 2, or 3.

[044] In another example, the disclosure relates to a compound of the formula I, or a pharmaceutically acceptable salt thereof,




I

[045] wherein

[060] n is 0, 1, 2, 3, or 4.

[061] In another example, the disclosure relates to a compound of the formula I, or a pharmaceutically acceptable salt thereof,



I

[062] wherein

[063] A is a ring selected from 5- to 10-membered heteroarylene or C_6-C_{10} arylene;

[064] X is $C(R^2)$ or N;

[065] X^1 is $C(R^3)$ or N;

[066] X^2 is $C(R^4)$ or N;

[067] Y is O, $N(R^5)C(O)$, $N(R^5)$, $N(R^6)$, S, S(O), $S(O)_2$, or Y is absent;

[068] Y^1 is O, $C(O)N(R^7)$, $N(R^8)$, S, S(O), $S(O)_2$, or Y^1 is absent;

[069] Y^2 is O, $C(O)N(R^9)$, $N(R^{10})$, S, S(O), $S(O)_2$, or Y^2 is absent;

[070] L is a C_1-C_6 alkylene, wherein each hydrogen atom in C_1-C_6 alkylene is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, 5- to 10-membered heteroaryl, $-OR^a$, $-OC(O)R^a$, $-OC(O)NR^aR^b$, $-OS(O)R^a$, $-OS(O)_2R^a$, $-SR^a$, $-S(O)R^a$, $-S(O)_2R^a$, $-S(O)NR^aR^b$, $-S(O)_2NR^aR^b$, $-OS(O)NR^aR^b$, $-OS(O)_2NR^aR^b$, $-NR^aR^b$, $-NR^aC(O)R^b$, $-NR^aC(O)OR^b$, $-NR^aC(O)NR^aR^b$, $-NR^aS(O)R^b$, $-NR^aS(O)_2R^b$, $-NR^aS(O)NR^aR^b$, $-NR^aS(O)_2NR^aR^b$, $-C(O)R^a$, $-C(O)OR^a$, $-C(O)NR^aR^b$, $-PR^aR^b$, $-P(O)R^aR^b$, $-P(O)_2R^aR^b$, $-P(O)NR^aR^b$, $-P(O)_2NR^aR^b$, $-P(O)OR^a$, $-P(O)_2OR^a$, -CN, or $-NO_2$;


[071] each L^1, when present, is independently C_1-C_6 alkylene or a ring B selected from the group consisting of 5- to 10-membered heteroarylene, 3- to 10-membered heterocycloalkylene, 3- to 6-membered cycloalkylene, and C_6-C_{10} arylene, wherein each hydrogen atom in 5- to 10-membered heteroarylene, 3- to 10-membered heterocycloalkylene, C_6-C_{10} arylene, and C_1-C_6 alkylene is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_2-

alkyl)$_2$, -P(O)N(C_2-C_6 alkylene), -P(O)$_2$N(H or C_1-C_6 alkyl)$_2$, -P(O)$_2$N(C_2-C_6 alkylene), -P(O)O(H or C_1-C_6 alkyl), -P(O)$_2$O(H or C_1-C_6 alkyl), -CN, or -NO_2;

[076] m is 0, 1, 2, 3, or 4; and

[077] n is 0, 1, 2, 3, or 4.

[078] In another example, the disclosure provides a compound of the formula IIa, or a pharmaceutically acceptable salt thereof,



IIa


[079] wherein R^1, R^{11}, A, L, X, X^1, X^2, Y, Y^1, Y^2, n, and o are as described herein;

[080] ring B is a 5- to 10-membered heteroarylene, 3- to 10-membered heterocycloalkylene, or C_6-C_{10} arylene, wherein each hydrogen atom in 3- to 10-membered heteroarylene, 5- to 10-membered heterocycloalkylene, and C_6-C_{10} arylene is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, 5- to 10-membered heteroaryl, -OR^c, -$OC(O)R^c$, -$OC(O)NR^cR^d$, -$OC(=N)NR^cR^d$, -$OS(O)R^c$, -$OS(O)_2R^c$, -$OS(O)NR^cR^d$, -$OS(O)_2NR^cR^d$, -SR^c, -$S(O)R^c$, -$S(O)_2R^c$, -$S(O)NR^cR^d$, -$S(O)_2NR^cR^d$, -NR^cR^d, -$NR^cC(O)R^d$, -$N(C(O)R^c)(C(O)R^d)$, -$NR^cC(O)OR^d$, -$NR^cC(O)NR^cR^d$, -$NR^cC(=N)NR^cR^d$, -$NR^cS(O)R^d$, -$NR^cS(O)_2R^d$, -$NR^cS(O)NR^cR^d$, -$NR^cS(O)_2NR^cR^d$, -$C(O)R^c$, -$C(O)OR^c$, -$C(O)NR^cR^d$, -$C(=N)NR^cR^d$, -PR^cR^d, -$P(O)R^cR^d$, -$P(O)_2R^cR^d$, -$P(O)NR^cR^d$, -$P(O)_2NR^cR^d$, -$P(O)OR^c$, -$P(O)_2OR^c$, -CN, or -NO_2; and

[081] L^1 is C_1-C_6 alkylene, wherein each hydrogen atom in C_1-C_6 alkylene is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, 5- to 10-membered heteroaryl, -OR^c, -$OC(O)R^c$, -$OC(O)NR^cR^d$, -$OC(=N)NR^cR^d$, -$OS(O)R^c$, -$OS(O)_2R^c$, -$OS(O)NR^cR^d$, -$OS(O)_2NR^cR^d$, -SR^c, -$S(O)R^c$, -$S(O)_2R^c$, -$S(O)NR^cR^d$, -$S(O)_2NR^cR^d$, -NR^cR^d, -$NR^cC(O)R^d$,

-N(C(O)R^c)(C(O)R^d), -NR^{c}C(O)OR^d, -NR^{c}C(O)NR^{c}R^d, -NR^{c}C(=N)NR^{c}R^d, -NR^{c}S(O)R^d, -NR^{c}S(O)$_2$R^d, -NR^{c}S(O)NR^{c}R^d, -NR^{c}S(O)$_2$NR^{c}R^d, -C(O)R^c, -C(O)OR^c, -C(O)NR^{c}R^d, -C(=N)NR^{c}R^d, -PR^{c}R^d, -P(O)R^{c}R^d, -P(O)$_2$R^{c}R^d, -P(O)NR^{c}R^d, -P(O)$_2$NR^{c}R^d, -P(O)OR^c, -P(O)$_2$OR^c, -CN, or -NO$_2$.

[082] In another example, the disclosure provides a compound of the formula II, or a pharmaceutically acceptable salt thereof,



II


[083] wherein R^1, R^{11}, A, L, X, X^1, X^2, Y, Y^1, Y^2, and n are as described herein;

[084] ring B is a 5- to 10-membered heteroarylene, 3- to 10-membered heterocycloalkylene, or C$_6$-C$_{10}$ arylene, wherein each hydrogen atom in 3- to 10-membered heteroarylene, 5- to 10-membered heterocycloalkylene, and C$_6$-C$_{10}$ arylene is independently optionally substituted by deuterium, halogen, C$_1$-C$_6$ alkyl, C$_2$-C$_6$ alkenyl, C$_2$-C$_6$ alkynyl, C$_3$-C$_6$ cycloalkyl, 3- to 7-membered heterocycloalkyl, C$_6$-C$_{10}$ aryl, 5- to 10-membered heteroaryl, -OR^c, -OC(O)R^c, -OC(O)NR^{c}R^d, -OC(=N)NR^{c}R^d, -OS(O)R^c, -OS(O)$_2$R^c, -OS(O)NR^{c}R^d, -OS(O)$_2$NR^{c}R^d, -SR^c, -S(O)R^c, -S(O)$_2$R^c, -S(O)NR^{c}R^d, -S(O)$_2$NR^{c}R^d, -NR^{c}R^d, -NR^{c}C(O)R^d, -N(C(O)R^c)(C(O)R^d), -NR^{c}C(O)OR^d, -NR^{c}C(O)NR^{c}R^d, -NR^{c}C(=N)NR^{c}R^d, -NR^{c}S(O)R^d, -NR^{c}S(O)$_2$R^d, -NR^{c}S(O)NR^{c}R^d, -NR^{c}S(O)$_2$NR^{c}R^d, -C(O)R^c, -C(O)OR^c, -C(O)NR^{c}R^d, -C(=N)NR^{c}R^d, -PR^{c}R^d, -P(O)R^{c}R^d, -P(O)$_2$R^{c}R^d, -P(O)NR^{c}R^d, -P(O)$_2$NR^{c}R^d, -P(O)OR^c, -P(O)$_2$OR^c, -CN, or -NO$_2$; and

[085] L^1 is C$_1$-C$_6$ alkylene, wherein each hydrogen atom in C$_1$-C$_6$ alkylene is independently optionally substituted by deuterium, halogen, C$_1$-C$_6$ alkyl, C$_2$-C$_6$ alkenyl, C$_2$-C$_6$ alkynyl, C$_3$-C$_6$ cycloalkyl, 3- to 7-membered heterocycloalkyl, C$_6$-C$_{10}$ aryl, 5- to 10-membered heteroaryl, -OR^c, -OC(O)R^c, -OC(O)NR^{c}R^d, -OC(=N)NR^{c}R^d, -OS(O)R^c, -OS(O)$_2$R^c, -OS(O)NR^{c}R^d,

$-OS(O)_2NR^cR^d$, $-SR^c$, $-S(O)R^c$, $-S(O)_2R^c$, $-S(O)NR^cR^d$, $-S(O)_2NR^cR^d$, $-NR^cR^d$, $-NR^cC(O)R^d$, $-N(C(O)R^c)(C(O)R^d)$, $-NR^cC(O)OR^d$, $-NR^cC(O)NR^cR^d$, $-NR^cC(=N)NR^cR^d$, $-NR^cS(O)R^d$, $-NR^cS(O)_2R^d$, $-NR^cS(O)NR^cR^d$, $-NR^cS(O)_2NR^cR^d$, $-C(O)R^c$, $-C(O)OR^c$, $-C(O)NR^cR^d$, $-C(=N)NR^cR^d$, $-PR^cR^d$, $-P(O)R^cR^d$, $-P(O)_2R^cR^d$, $-P(O)NR^cR^d$, $-P(O)_2NR^cR^d$, $-P(O)OR^c$, $-P(O)_2OR^c$, -CN, or $-NO_2$.

[086] In another example, the disclosure provides a compound of the formula IIIa, or a pharmaceutically acceptable salt thereof,




IIIa

[087] wherein R^1, R^{11}, A, L, X, X^1, X^2, Y, Y^1, Y^2, n, and o are as described herein; and.

[088] L^1 is C_1-C_6 alkylene, wherein each hydrogen atom in C_1-C_6 alkylene is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, 5- to 10-membered heteroaryl, $-OR^c$, $-OC(O)R^c$, $-OC(O)NR^cR^d$, $-OC(=N)NR^cR^d$, $-OS(O)R^c$, $-OS(O)_2R^c$, $-OS(O)NR^cR^d$, $-OS(O)_2NR^cR^d$, $-SR^c$, $-S(O)R^c$, $-S(O)_2R^c$, $-S(O)NR^cR^d$, $-S(O)_2NR^cR^d$, $-NR^cR^d$, $-NR^cC(O)R^d$, $-N(C(O)R^c)(C(O)R^d)$, $-NR^cC(O)OR^d$, $-NR^cC(O)NR^cR^d$, $-NR^cC(=N)NR^cR^d$, $-NR^cS(O)R^d$, $-NR^cS(O)_2R^d$, $-NR^cS(O)NR^cR^d$, $-NR^cS(O)_2NR^cR^d$, $-C(O)R^c$, $-C(O)OR^c$, $-C(O)NR^cR^d$, $-C(=N)NR^cR^d$, $-PR^cR^d$, $-P(O)R^cR^d$, $-P(O)_2R^cR^d$, $-P(O)NR^cR^d$, $-P(O)_2NR^cR^d$, $-P(O)OR^c$, $-P(O)_2OR^c$, -CN, or $-NO_2$.

[089] In another example, the disclosure provides a compound of the formula III, or a pharmaceutically acceptable salt thereof,




III

[090] wherein R^1, R^{11}, A, L, X, X^1, X^2, Y, Y^1, Y^2, and n are as described herein; and.

[091] L^1 is C_1-C_6 alkylene, wherein each hydrogen atom in C_1-C_6 alkylene is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, 5- to 10-membered heteroaryl, $-OR^c$, $-OC(O)R^c$, $-OC(O)NR^cR^d$, $-OC(=N)NR^cR^d$, $-OS(O)R^c$, $-OS(O)_2R^c$, $-OS(O)NR^cR^d$, $-OS(O)_2NR^cR^d$, $-SR^c$, $-S(O)R^c$, $-S(O)_2R^c$, $-S(O)NR^cR^d$, $-S(O)_2NR^cR^d$, $-NR^cR^d$, $-NR^cC(O)R^d$, $-N(C(O)R^c)(C(O)R^d)$, $-NR^cC(O)OR^d$, $-NR^cC(O)NR^cR^d$, $-NR^cC(=N)NR^cR^d$, $-NR^cS(O)R^d$, $-NR^cS(O)_2R^d$, $-NR^cS(O)NR^cR^d$, $-NR^cS(O)_2NR^cR^d$, $-C(O)R^c$, $-C(O)OR^c$, $-C(O)NR^cR^d$, $-C(=N)NR^cR^d$, $-PR^cR^d$, $-P(O)R^cR^d$, $-P(O)_2R^cR^d$, $-P(O)NR^cR^d$, $-P(O)_2NR^cR^d$, $-P(O)OR^c$, $-P(O)_2OR^c$, -CN, or $-NO_2$.

[092] In another example, the disclosure relates to a compound of the formula IVa, or a pharmaceutically acceptable salt thereof,



IVa


[093] wherein

alkyl)C(O)N(C_2-C_6 alkylene), -N(H or C_1-C_6 alkyl)S(O)-(H or C_1-C_6 alkyl), -N(H or C_1-C_6 alkyl)S(O)$_2$(H or C_1-C_6 alkyl), -N(H or C_1-C_6 alkyl)S(O)N(H or C_1-C_6 alkyl)$_2$, -N(H or C_1-C_6 alkyl)S(O)N(C_2-C_6 alkylene), -N(H or C_1-C_6 alkyl)S(O)$_2$N(H or C_1-C_6 alkyl)$_2$, -N(H or C_1-C_6 alkyl)S(O)$_2$N(C_2-C_6 alkylene), -C(O)-(H or C_1-C_6 alkyl), -C(O)O(H or C_1-C_6 alkyl), -C(O)N(C_2-C_6 alkylene), -P(H or C_1-C_6 alkyl)$_2$, -P(C_2-C_6 alkylene), -P(O)(H or C_1-C_6 alkyl)$_2$, -P(O)(C_2-C_6 alkylene), -P(O)$_2$(H or C_1-C_6 alkyl)$_2$, -P(O)$_2$(C_2-C_6 alkylene), -P(O)N(H or C_1-C_6 alkyl)$_2$, -P(O)N(C_2-C_6 alkylene), -P(O)$_2$N(H or C_1-C_6 alkyl)$_2$, -P(O)$_2$N(C_2-C_6 alkylene), -P(O)O(H or C_1-C_6 alkyl), -P(O)$_2$O(H or C_1-C_6 alkyl), -CN, or -NO_2;

[0105] n is 0, 1, 2, 3, or 4; and

[0106] o is 0, 1, 2, or 3.

[0107] In another example, the disclosure relates to a compound of the formula IV, or a pharmaceutically acceptable salt thereof,



IV

[0108] wherein

[0109] ring A is a ring selected from 5- to 10-membered heteroarylene or C_6-C_{10} arylene;

[0110] Y is O, N(R^5)C(O), S, S(O), or S(O)$_2$;

[0111] Y^1 is O, S, S(O), or S(O)$_2$;

[0112] L is a C_1-C_6 alkylene, wherein each hydrogen atom in C_1-C_6 alkylene is independently optionally substituted by deuterium;

[0113] L^1 is absent, or L^1 is C_1-C_6 alkylene, wherein each hydrogen atom in C_1-C_6 alkylene is independently optionally substituted by deuterium or C_1-C_6 alkyl;

[0114] ring B is a 5- to 10-membered heteroarylene or C_6-C_{10} arylene, wherein each hydrogen atom in 3- to 10-membered heteroarylene or C_6-C_{10} arylene is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, 5- to 10-membered heteroaryl, -OR^c,

substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, -OH, -OC_1-C_6 alkyl, -OC(O)-(H or C_1-C_6 alkyl), -OC(O)N(H or C_1-C_6 alkyl)$_2$, -OC(O)N(C_2-C_6 alkylene), -OS(O)-(H or C_1-C_6 alkyl), -OS(O)$_2$-(H or C_1-C_6 alkyl), -OS(O)N(H or C_1-C_6 alkyl)$_2$, -OS(O)N(C_2-C_6 alkylene), -OS(O)$_2$N(H or C_1-C_6 alkyl)$_2$, -OS(O)$_2$N(C_2-C_6 alkylene), -S(H or C_1-C_6 alkyl), -S(O)(H or C_1-C_6 alkyl), -S(O)$_2$(H or C_1-C_6 alkyl), -S(O)N(H or C_1-C_6 alkyl)$_2$, -S(O)N(C_2-C_6 alkylene), -S(O)$_2$N(H or C_1-C_6 alkyl)$_2$, -S(O)$_2$N(C_2-C_6 alkylene), -N(H or C_1-C_6 alkyl)$_2$, -N(C_2-C_6 alkylene), -N(H or C_1-C_6 alkyl)C(O)-(H or C_1-C_6 alkyl), -N(H or C_1-C_6 alkyl)C(O)O(H or C_1-C_6 alkyl), -N(H or C_1-C_6 alkyl)C(O)N(H or C_1-C_6 alkyl)$_2$, -N(H or C_1-C_6 alkyl)C(O)N(C_2-C_6 alkylene), -N(H or C_1-C_6 alkyl)S(O)-(H or C_1-C_6 alkyl), -N(H or C_1-C_6 alkyl)S(O)$_2$(H or C_1-C_6 alkyl), -N(H or C_1-C_6 alkyl)S(O)N(H or C_1-C_6 alkyl)$_2$, -N(H or C_1-C_6 alkyl)S(O)N(C_2-C_6 alkylene), -N(H or C_1-C_6 alkyl)S(O)$_2$N(H or C_1-C_6 alkyl)$_2$, -N(H or C_1-C_6 alkyl)S(O)$_2$N(C_2-C_6 alkylene), -C(O)-(H or C_1-C_6 alkyl), -C(O)O(H or C_1-C_6 alkyl), -C(O)N(C_2-C_6 alkylene), -P(H or C_1-C_6 alkyl)$_2$, -P(C_2-C_6 alkylene), -P(O)(H or C_1-C_6 alkyl)$_2$, -P(O)(C_2-C_6 alkylene), -P(O)$_2$(H or C_1-C_6 alkyl)$_2$, -P(O)$_2$(C_2-C_6 alkylene), -P(O)N(H or C_1-C_6 alkyl)$_2$, -P(O)N(C_2-C_6 alkylene), -P(O)$_2$N(H or C_1-C_6 alkyl)$_2$, -P(O)$_2$N(C_2-C_6 alkylene), -P(O)O(H or C_1-C_6 alkyl), -P(O)$_2$O(H or C_1-C_6 alkyl), -CN, or -NO_2; and

[0118] n is 0, 1, 2, 3, or 4.

[0119] In certain examples, the compound of Formula (Ia)-(IXa) or (I)-(IX) is a compound selected from those species described or exemplified in the detailed description below.

[0120a] In another aspect, there is provided a pharmaceutical composition comprising a compound of any one of the preceding claims, and optionally one or more excipients.

[0120] In further examples, the disclosure relates to a pharmaceutical composition comprising at least one compound of Formula (Ia)-(IXa) or (I)-(IX) or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions according to the disclosure may further comprise a pharmaceutically acceptable excipient.

[0121] In further examples, the disclosure relates to a compound of Formula (Ia)-(IXa) or (I)-(IX), or a pharmaceutically acceptable salt thereof, for use as a medicament.

[0122] In further examples, the disclosure relates to a method of treating disease, such as cancer comprising administering to a subject in need of such treatment an effective amount of at least one compound of Formula (Ia)-(IXa) or (I)-(IX), or a pharmaceutically acceptable salt thereof.

[0122a] In another aspect, there is provided the use of a compound as defined above in the manufacture of a medicament for the treatment of disease in a subject.


[0123] In further examples, the disclosure relates to use of a compound of Formula (Ia)-(IXa) or (I)-(IX), or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment of disease, such as cancer, and the use of such compounds and salts for treatment of such diseases.

[0124] In further examples, the disclosure relates to a method of inhibiting a tyrosine kinase, such as EGFR, comprising contacting a cell comprising one or more of kinase with an effective

amount of at least one compound of Formula (Ia)-(IXa) or (I)-(IX), or a pharmaceutically acceptable salt thereof, and/or with at least one pharmaceutical composition of the disclosure, wherein the contacting is *in vitro, ex vivo,* or *in vivo*.

[0125] Additional examples, features, and advantages of the disclosure will be apparent from the following detailed description and through practice of the disclosure. The compounds of the present disclosure can be described as examples in any of the following enumerated clauses. It will be understood that any of the examples described herein can be used in connection with any other examples described herein to the extent that the embodiments do not contradict one another.

[0126] 1. A compound of the formula Ia, or a pharmaceutically acceptable salt thereof,



Ia

[0127] wherein

[0128] A is a ring selected from 5- to 10-membered heteroarylene or C_6-C_{10} arylene;

[0129] X is $C(R^2)$ or N;

[0130] X^1 is $C(R^3)$ or N;

[0131] X^2 is $C(R^4)$ or N;

[0132] Y is O, $N(R^5)C(O)$, $C(O)N(R^5)$, $N(R^6)$, $N(R^5)S(O)$, $S(O)N(R^5)$, $N(R^5)S(O)_2$, $S(O)_2N(R^5)$, S, S(O), $S(O)_2$, or Y is absent;


[0133] each Y^1 is independently O, $C(O)N(R^7)$, $N(R^7)C(O)$, $N(R^8)$, $N(R^7)S(O)$, $S(O)N(R^7)$, $N(R^7)S(O)_2$, $S(O)_2N(R^7)$, S, S(O), $S(O)_2$, or absent;

[0134] Y^2 is O, $C(O)N(R^9)$, $N(R^9)C(O)$, $N(R^{10})$, $N(R^9)S(O)$, $S(O)N(R^9)$, $N(R^9)S(O)_2$, $S(O)_2N(R^9)$, S, S(O), $S(O)_2$, or Y^2 is absent;

[0135] each L is independently a C_1-C_6 alkylene, wherein each hydrogen atom in C_1-C_6 alkylene is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, 5-

WHAT IS CLAIMED IS:

1. A compound of the formula Ia



Ia

wherein

A is a ring selected from 5- to 10-membered heteroarylene or C_6-C_{10} arylene;

X is $C(R^2)$ or N;

X^1 is $C(R^3)$ or N;

X^2 is $C(R^4)$ or N;

Y is O, $N(R^5)C(O)$, $C(O)N(R^5)$, $N(R^6)$, $N(R^5)S(O)$, $S(O)N(R^5)$, $N(R^5)S(O)_2$, $S(O)_2N(R^5)$, S, S(O), $S(O)_2$, or Y is absent;

each Y^1 is independently O, $C(O)N(R^7)$, $N(R^7)C(O)$, $N(R^8)$, $N(R^7)S(O)$, $S(O)N(R^7)$, $N(R^7)S(O)_2$, $S(O)_2N(R^7)$, S, S(O), $S(O)_2$, or absent;

Y^2 is O, $C(O)N(R^9)$, $N(R^9)C(O)$, $N(R^{10})$, $N(R^9)S(O)$, $S(O)N(R^9)$, $N(R^9)S(O)_2$, $S(O)_2N(R^9)$, S, S(O), $S(O)_2$, or Y^2 is absent;

each L is independently a C_1-C_6 alkylene, wherein each hydrogen atom in C_1-C_6 alkylene is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, 5- to 10-membered heteroaryl, $-OR^a$, $-OC(O)R^a$, $-OC(O)NR^aR^b$, $-OS(O)R^a$, $-OS(O)_2R^a$, $-SR^a$, $-S(O)R^a$, $-S(O)_2R^a$, $-S(O)NR^aR^b$, $-S(O)_2NR^aR^b$, $-OS(O)NR^aR^b$, $-OS(O)_2NR^aR^b$, $-NR^aR^b$, $-NR^aC(O)R^b$, $-NR^aC(O)OR^b$, $-NR^aC(O)NR^aR^b$, $-NR^aS(O)R^b$, $-NR^aS(O)_2R^b$, $-NR^aS(O)NR^aR^b$, $-NR^aS(O)_2NR^aR^b$, $-C(O)R^a$, $-C(O)OR^a$, $-C(O)NR^aR^b$, $-PR^aR^b$, $-P(O)R^aR^b$, $-P(O)_2R^aR^b$, $-P(O)NR^aR^b$, $-P(O)_2NR^aR^b$, $-P(O)OR^a$, $-P(O)_2OR^a$, -CN, or $-NO_2$; or optionally two hydrogen atoms on one carbon atom in C_1-C_6 alkylene are optionally substituted by a C_2-C_5 alkylene to provide a C_3-C_6 cycloalkylene; or optionally two hydrogen atoms on two carbon atoms in C_1-C_6 alkylene are optionally substituted by a C_1-C_4 alkylene to provide a C_3-C_6 cycloalkylene;

or optionally one hydrogen atom on one carbon atom in C_1-C_6 alkylene and one of R^5, R^6, R^7, or R^8 taken together with the atoms to which they are attached combine to form a 3- to 7-membered heterocycloalkylene;

each L^1, when present, is independently C_1-C_6 alkylene or a ring B selected from the group consisting of 5- to 10-membered heteroarylene, 3- to 10-membered heterocycloalkylene, 3- to 6-membered cycloalkylene, and C_6-C_{10} arylene, wherein each hydrogen atom in 5- to 10-membered heteroarylene, 3- to 10-membered heterocycloalkylene, C_6-C_{10} arylene, and C_1-C_6 alkylene is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, 5- to 10-membered heteroaryl, $-OR^c$, $-OC(O)R^c$, $-OC(O)NR^cR^d$, $-OC(=N)NR^cR^d$, $-OS(O)R^c$, $-OS(O)_2R^c$, $-OS(O)NR^cR^d$, $-OS(O)_2NR^cR^d$, $-SR^c$, $-S(O)R^c$, $-S(O)_2R^c$, $-S(O)NR^cR^d$, $-S(O)_2NR^cR^d$, $-NR^cR^d$, $-NR^cC(O)R^d$, $-N(C(O)R^c)(C(O)R^d)$, $-NR^cC(O)OR^d$, $-NR^cC(O)NR^cR^d$, $-NR^cC(=N)NR^cR^d$, $-NR^cS(O)R^d$, $-NR^cS(O)_2R^d$, $-NR^cS(O)NR^cR^d$, $-NR^cS(O)_2NR^cR^d$, $-C(O)R^c$, $-C(O)OR^c$, $-C(O)NR^cR^d$, $-C(=N)NR^cR^d$, $-PR^cR^d$, $-P(O)R^cR^d$, $-P(O)_2R^cR^d$, $-P(O)NR^cR^d$, $-P(O)_2NR^cR^d$, $-P(O)OR^c$, $-P(O)_2OR^c$, -CN, or $-NO_2$;

each R^1 is independently deuterium, halogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, 5- to 10-membered heteroaryl, $-OR^a$, $-OC(O)R^a$, $-OC(O)NR^aR^b$, $-OS(O)R^a$, $-OS(O)_2R^a$, $-SR^a$, $-S(O)R^a$, $-S(O)_2R^a$, $-S(O)NR^aR^b$, $-S(O)_2NR^aR^b$, $-OS(O)NR^aR^b$, $-OS(O)_2NR^aR^b$, $-NR^aR^b$, $-NR^aC(O)R^b$, $-NR^aC(O)OR^b$, $-NR^aC(O)NR^aR^b$, $-NR^aS(O)R^b$, $-NR^aS(O)_2R^b$, $-NR^aS(O)NR^aR^b$, $-NR^aS(O)_2NR^aR^b$, $-C(O)R^a$, $-C(O)OR^a$, $-C(O)NR^aR^b$, $-PR^aR^b$, $-P(O)R^aR^b$, $-P(O)_2R^aR^b$, $-P(O)NR^aR^b$, $-P(O)_2NR^aR^b$, $-P(O)OR^a$, $-P(O)_2OR^a$, -CN, or $-NO_2$, wherein each hydrogen atom in C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, or 5- to 10-membered heteroaryl, is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, $-OR^e$, $-OC(O)R^e$, $-OC(O)NR^eR^f$, $-OS(O)R^e$, $-OS(O)_2R^e$, $-OS(O)NR^eR^f$, $-OS(O)_2NR^eR^f$, $-SR^e$, $-S(O)R^e$, $-S(O)_2R^e$, $-S(O)NR^eR^f$, $-S(O)_2NR^eR^f$, $-NR^eR^f$, $-NR^eC(O)R^f$, $-NR^eC(O)OR^f$, $-NR^eC(O)NR^eR^f$, $-NR^eS(O)R^f$, $-NR^eS(O)_2R^f$, $-NR^eS(O)NR^eR^f$, $-NR^eS(O)_2NR^eR^f$, $-C(O)R^e$, $-C(O)OR^e$, $-C(O)NR^eR^f$, $-PR^eR^f$, $-P(O)R^eR^f$, $-P(O)_2R^eR^f$, $-P(O)NR^eR^f$, $-P(O)_2NR^eR^f$, $-P(O)OR^e$, $-P(O)_2OR^e$, -CN, or $-NO_2$;

each of R^2, R^3, and R^4, when present, is independently H, deuterium, halogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, 5- to 10-membered heteroaryl, $-OR^a$, $-OC(O)R^a$, $-OC(O)NR^aR^b$, $-OS(O)R^a$, $-OS(O)_2R^a$, $-SR^a$, $-S(O)R^a$, $-S(O)_2R^a$, $-S(O)NR^aR^b$, $-S(O)_2NR^aR^b$, $-OS(O)NR^aR^b$, $-OS(O)_2NR^aR^b$, $-NR^aR^b$, $-NR^aC(O)R^b$, $-NR^aC(O)OR^b$, $-NR^aC(O)NR^aR^b$, $-NR^aS(O)R^b$,

$-NR^aS(O)_2R^b$, $-NR^aS(O)NR^aR^b$, $-NR^aS(O)_2NR^aR^b$, $-C(O)R^a$, $-C(O)OR^a$, $-C(O)NR^aR^b$, $-PR^aR^b$, $-P(O)R^aR^b$, $-P(O)_2R^aR^b$, $-P(O)NR^aR^b$, $-P(O)_2NR^aR^b$, $-P(O)OR^a$, $-P(O)_2OR^a$, -CN, or $-NO_2$, wherein each hydrogen atom in C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, and 5- to 10-membered heteroaryl, is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, $-OR^e$, $-OC(O)R^e$, $-OC(O)NR^eR^f$, $-OS(O)R^e$, $-OS(O)_2R^e$, $-OS(O)NR^eR^f$, $-OS(O)_2NR^eR^f$, $-SR^e$, $-S(O)R^e$, $-S(O)_2R^e$, $-S(O)NR^eR^f$, $-S(O)_2NR^eR^f$, $-NR^eR^f$, $-NR^eC(O)R^f$, $-NR^eC(O)OR^f$, $-NR^eC(O)NR^eR^f$, $-NR^eS(O)R^f$, $-NR^eS(O)_2R^f$, $-NR^eS(O)NR^eR^f$, $-NR^eS(O)_2NR^eR^f$, $-C(O)R^e$, $-C(O)OR^e$, $-C(O)NR^eR^f$, $-PR^eR^f$, $-P(O)R^eR^f$, $-P(O)_2R^eR^f$, $-P(O)NR^eR^f$, $-P(O)_2NR^eR^f$, $-P(O)OR^e$, $-P(O)_2OR^e$, -CN, or $-NO_2$;

each of R^5, R^6, R^7, R^8, R^9, R^{10}, and R^{11}, when present, is independently H, deuterium, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, or 5- to 10-membered heteroaryl, wherein each hydrogen atom in C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, or 5- to 10-membered heteroaryl is independently optionally substituted by $-OR^c$, $-OC(O)R^c$, $-OC(O)NR^cR^d$, $-OC(=N)NR^cR^d$, $-OS(O)R^c$, $-OS(O)_2R^c$, $-OS(O)NR^cR^d$, $-OS(O)_2NR^cR^d$, $-SR^c$, $-S(O)R^c$, $-S(O)_2R^c$, $-S(O)NR^cR^d$, $-S(O)_2NR^cR^d$, $-NR^cR^d$, $-NR^cC(O)R^d$, $-N(C(O)R^c)(C(O)R^d)$, $-NR^cC(O)OR^d$, $-NR^cC(O)NR^cR^d$, $-NR^cC(=N)NR^cR^d$, $-NR^cS(O)R^d$, $-NR^cS(O)_2R^d$, $-NR^cS(O)NR^cR^d$, $-NR^cS(O)_2NR^cR^d$, $-C(O)R^c$, $-C(O)OR^c$, $-C(O)NR^cR^d$, $-C(=N)NR^cR^d$, $-PR^cR^d$, $-P(O)R^cR^d$, $-P(O)_2R^cR^d$, $-P(O)NR^cR^d$, $-P(O)_2NR^cR^d$, $-P(O)OR^c$, $-P(O)_2OR^c$, -CN, or $-NO_2$;

each R^a, R^b, R^c, R^d, R^e, and R^f is independently selected from the group consisting of H, deuterium, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, C_1-C_6 alkylene-C_6-C_{10} aryl, 5- to 10-membered heteroaryl, and C_1-C_6 alkylene-5- to 10-membered heteroaryl, or R^a and R^b or R^c and R^d or R^e and R^f, taken together with the atom to which they are attached, form a a 3- to 7-membered heterocycloalkyl, wherein each hydrogen atom in C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, C_1-C_6 alkylene-C_6-C_{10} aryl, 5- to 10-membered heteroaryl, or C_1-C_6 alkylene-5- to 10-membered heteroaryl is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, -OH, -OC_1-C_6 alkyl, -OC(O)-(H or C_1-C_6 alkyl), -OC(O)N(H or C_1-C_6 alkyl)$_2$, -OC(O)N(C_2-C_6 alkylene), -OS(O)-(H or C_1-C_6 alkyl), -OS(O)$_2$-(H or C_1-C_6 alkyl), -OS(O)N(H or C_1-C_6 alkyl)$_2$, -OS(O)N(C_2-C_6 alkylene), -OS(O)$_2$N(H or C_1-C_6 alkyl)$_2$, -OS(O)$_2$N(C_2-C_6 alkylene), -S(H or C_1-C_6 alkyl), -S(O)(H or C_1-C_6 alkyl), -S(O)$_2$(H or C_1-C_6 alkyl), -S(O)N(H or C_1-C_6 alkyl)$_2$, -S(O)N(C_2-C_6 alkylene), -S(O)$_2$N(H or C_1-C_6 alkyl)$_2$, -S(O)$_2$N(C_2-C_6 alkylene), -N(H or C_1-C_6 alkyl)$_2$,

-N(C_2-C_6 alkylene), -N(H or C_1-C_6 alkyl)C(O)-(H or C_1-C_6 alkyl), -N(H or C_1-C_6 alkyl)C(O)O(H or C_1-C_6 alkyl), -N(H or C_1-C_6 alkyl)C(O)N(H or C_1-C_6 alkyl)$_2$, -N(H or C_1-C_6 alkyl)C(O)N(C_2-C_6 alkylene), -N(H or C_1-C_6 alkyl)S(O)-(H or C_1-C_6 alkyl), -N(H or C_1-C_6 alkyl)S(O)$_2$(H or C_1-C_6 alkyl), -N(H or C_1-C_6 alkyl)S(O)N(H or C_1-C_6 alkyl)$_2$, -N(H or C_1-C_6 alkyl)S(O)N(C_2-C_6 alkylene), -N(H or C_1-C_6 alkyl)S(O)$_2$N(H or C_1-C_6 alkyl)$_2$, -N(H or C_1-C_6 alkyl)S(O)$_2$N(C_2-C_6 alkylene), -C(O)-(H or C_1-C_6 alkyl), -C(O)O(H or C_1-C_6 alkyl), -C(O)N(C_2-C_6 alkylene), -P(H or C_1-C_6 alkyl)$_2$, -P(C_2-C_6 alkylene), -P(O)(H or C_1-C_6 alkyl)$_2$, -P(O)(C_2-C_6 alkylene), -P(O)$_2$(H or C_1-C_6 alkyl)$_2$, -P(O)$_2$(C_2-C_6 alkylene), -P(O)N(H or C_1-C_6 alkyl)$_2$, -P(O)N(C_2-C_6 alkylene), -P(O)$_2$N(H or C_1-C_6 alkyl)$_2$, -P(O)$_2$N(C_2-C_6 alkylene), -P(O)O(H or C_1-C_6 alkyl), -P(O)$_2$O(H or C_1-C_6 alkyl), -CN, or -NO_2;


m is 0, 1, 2, 3, or 4;

n is 0, 1, 2, 3, or 4; and

o is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, having the formula IVa



IVa

wherein

ring A is a ring selected from 5- to 10-membered heteroarylene or C_6-C_{10} arylene;

X^1 is C(R^3) or N;

Y is O, N(R^5)C(O), S, S(O), or S(O)$_2$;

each Y^1 is indepedently O, S, S(O), or S(O)$_2$;

each L is independently a C_1-C_6 alkylene, wherein each hydrogen atom in C_1-C_6 alkylene is independently optionally substituted by deuterium;

L^1 is absent, or L^1 is C_1-C_6 alkylene, wherein each hydrogen atom in C_1-C_6 alkylene is independently optionally substituted by deuterium or C_1-C_6 alkyl;

ring B is a 5- to 10-membered heteroarylene or C_6-C_{10} arylene, wherein each hydrogen atom in 5- to 10-membered heteroarylene or C_6-C_{10} arylene is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, 5- to 10-membered heteroaryl, $-OR^c$, $-OC(O)R^c$, $-OC(O)NR^cR^d$, $-OC(=N)NR^cR^d$, $-OS(O)R^c$, $-OS(O)_2R^c$, $-OS(O)NR^cR^d$, $-OS(O)_2NR^cR^d$, $-SR^c$, $-S(O)R^c$, $-S(O)_2R^c$, $-S(O)NR^cR^d$, $-S(O)_2NR^cR^d$, $-NR^cR^d$, $-NR^cC(O)R^d$, $-N(C(O)R^c)(C(O)R^d)$, $-NR^cC(O)OR^d$, $-NR^cC(O)NR^cR^d$, $-NR^cC(=N)NR^cR^d$, $-NR^cS(O)R^d$, $-NR^cS(O)_2R^d$, $-NR^cS(O)NR^cR^d$, $-NR^cS(O)_2NR^cR^d$, $-C(O)R^c$, $-C(O)OR^c$, $-C(O)NR^cR^d$, $-C(=N)NR^cR^d$, $-PR^cR^d$, $-P(O)R^cR^d$, $-P(O)_2R^cR^d$, $-P(O)NR^cR^d$, $-P(O)_2NR^cR^d$, $-P(O)OR^c$, $-P(O)_2OR^c$, -CN, or $-NO_2$;

each R^1 is independently deuterium, halogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, C_6-C_{10} aryl, 5- to 10-membered heteroaryl, $-OR^a$, $-OC(O)R^a$, $-OC(O)NR^aR^b$, $-OS(O)R^a$, $-OS(O)_2R^a$, $-SR^a$, $-S(O)R^a$, $-S(O)_2R^a$, $-S(O)NR^aR^b$, $-S(O)_2NR^aR^b$, $-OS(O)NR^aR^b$, $-OS(O)_2NR^aR^b$, $-NR^aC(O)R^b$, $-NR^aC(O)OR^b$, $-NR^aC(O)NR^aR^b$, $-NR^aS(O)R^b$, $-NR^aS(O)_2R^b$, $-NR^aS(O)NR^aR^b$, $-NR^aS(O)_2NR^aR^b$, $-C(O)R^a$, $-C(O)OR^a$, $-C(O)NR^aR^b$, $-PR^aR^b$, $-P(O)R^aR^b$, $-P(O)_2R^aR^b$, $-P(O)NR^aR^b$, $-P(O)_2NR^aR^b$, $-P(O)OR^a$, $-P(O)_2OR^a$, -CN, or $-NO_2$, wherein each hydrogen atom in C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, or 5- to 10-membered heteroaryl, is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, $-OR^e$, $-OC(O)R^e$, $-OC(O)NR^eR^f$, $-OS(O)R^e$, $-OS(O)_2R^e$, $-OS(O)NR^eR^f$, $-OS(O)_2NR^eR^f$, $-SR^e$, $-S(O)R^e$, $-S(O)_2R^e$, $-S(O)NR^eR^f$, $-S(O)_2NR^eR^f$, $-NR^eC(O)R^f$, $-NR^eC(O)OR^f$, $-NR^eC(O)NR^eR^f$, $-NR^eS(O)R^f$, $-NR^eS(O)_2R^f$, $-NR^eS(O)NR^eR^f$, $-NR^eS(O)_2NR^eR^f$, $-C(O)R^e$, $-C(O)OR^e$, $-C(O)NR^eR^f$, $-PR^eR^f$, $-P(O)R^eR^f$, $-P(O)_2R^eR^f$, $-P(O)NR^eR^f$, $-P(O)_2NR^eR^f$, $-P(O)OR^e$, $-P(O)_2OR^e$, -CN, or $-NO_2$;

R^3, when present, is independently H, deuterium, halogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, 5- to 10-membered heteroaryl, $-OR^a$, $-OC(O)R^a$, $-OC(O)NR^aR^b$, $-OS(O)R^a$, $-OS(O)_2R^a$, $-SR^a$, $-S(O)R^a$, $-S(O)_2R^a$, $-S(O)NR^aR^b$, $-S(O)_2NR^aR^b$, $-OS(O)NR^aR^b$, $-OS(O)_2NR^aR^b$, $-NR^aR^b$, $-NR^aC(O)R^b$, $-NR^aC(O)OR^b$, $-NR^aC(O)NR^aR^b$, $-NR^aS(O)R^b$, $-NR^aS(O)_2R^b$, $-NR^aS(O)NR^aR^b$, $-NR^aS(O)_2NR^aR^b$, $-C(O)R^a$, $-C(O)OR^a$, $-C(O)NR^aR^b$, $-PR^aR^b$, $-P(O)R^aR^b$, $-P(O)_2R^aR^b$, $-P(O)NR^aR^b$, $-P(O)_2NR^aR^b$, $-P(O)OR^a$, $-P(O)_2OR^a$, -CN, or $-NO_2$, wherein each hydrogen atom in C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, and 5- to 10-membered heteroaryl, is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, $-OR^e$, $-OC(O)R^e$,

-OC(O)NR^{e}R^f, -OS(O)R^e, -OS(O)$_2$R^e, -OS(O)NR^{e}R^f, -OS(O)$_2$NR^{e}R^f, -SR^e, -S(O)R^e, -S(O)$_2$R^e, -S(O)NR^{e}R^f, -S(O)$_2$NR^{e}R^f, -NR^{e}R^f, -NR^{e}C(O)R^f, -NR^{e}C(O)OR^f, -NR^{e}C(O)NR^{e}R^f, -NR^{e}S(O)R^f, -NR^{e}S(O)$_2$R^f, -NR^{e}S(O)NR^{e}R^f, -NR^{e}S(O)$_2$NR^{e}R^f, -C(O)R^e, -C(O)OR^e, -C(O)NR^{e}R^f, -PR^{e}R^f, -P(O)R^{e}R^f, -P(O)$_2$R^{e}R^f, -P(O)NR^{e}R^f, -P(O)$_2$NR^{e}R^f, -P(O)OR^e, -P(O)$_2$OR^e, -CN, or -NO$_2$;

each of R^5, and R^{11}, when present, is independently H, deuterium, halogen, C$_1$-C$_6$ alkyl, C$_2$-C$_6$ alkenyl, C$_2$-C$_6$ alkynyl, C$_3$-C$_6$ cycloalkyl, 3- to 7-membered heterocycloalkyl, C$_6$-C$_{10}$ aryl, 5- to 10-membered heteroaryl, -OR^c, -OC(O)R^c, -OC(O)NR^{c}R^d, -OC(=N)NR^{c}R^d, -OS(O)R^c, -OS(O)$_2$R^c, -OS(O)NR^{c}R^d, -OS(O)$_2$NR^{c}R^d, -SR^c, -S(O)R^c, -S(O)$_2$R^c, -S(O)NR^{c}R^d, -S(O)$_2$NR^{c}R^d, -NR^{c}R^d, -NR^{c}C(O)R^d, -N(C(O)R^c)(C(O)R^d), -NR^{c}C(O)OR^d, -NR^{c}C(O)NR^{c}R^d, -NR^{c}C(=N)NR^{c}R^d, -NR^{c}S(O)R^d, -NR^{c}S(O)$_2$R^d, -NR^{c}S(O)NR^{c}R^d, -NR^{c}S(O)$_2$NR^{c}R^d, -C(O)R^c, -C(O)OR^c, -C(O)NR^{c}R^d, -C(=N)NR^{c}R^d, -PR^{c}R^d, -P(O)R^{c}R^d, -P(O)$_2$R^{c}R^d, -P(O)NR^{c}R^d, -P(O)$_2$NR^{c}R^d, -P(O)OR^c, -P(O)$_2$OR^c, -CN, or -NO$_2$;


each R^a, R^b, R^c, R^d, R^e, and R^f is independently selected from the group consisting of H, deuterium, C$_1$-C$_6$ alkyl, C$_2$-C$_6$ alkenyl, C$_2$-C$_6$ alkynyl, C$_3$-C$_6$ cycloalkyl, 3- to 7-membered heterocycloalkyl, C$_6$-C$_{10}$ aryl, C$_1$-C$_6$ alkylene-C$_6$-C$_{10}$ aryl, 5- to 10-membered heteroaryl, and C$_1$-C$_6$ alkylene-5- to 10-membered heteroaryl, or R^a and R^b or R^c and R^d or R^e and R^f, taken together with the atom to which they are attached, form a a 3- to 7-membered heterocycloalkyl, wherein each hydrogen atom in C$_1$-C$_6$ alkyl, C$_2$-C$_6$ alkenyl, C$_2$-C$_6$ alkynyl, C$_3$-C$_6$ cycloalkyl, 3- to 7-membered heterocycloalkyl, C$_6$-C$_{10}$ aryl, C$_1$-C$_6$ alkylene-C$_6$-C$_{10}$ aryl, 5- to 10-membered heteroaryl, or C$_1$-C$_6$ alkylene-5- to 10-membered heteroaryl is independently optionally substituted by deuterium, halogen, C$_1$-C$_6$ alkyl, C$_1$-C$_6$ haloalkyl, -OH, -OC$_1$-C$_6$ alkyl, -OC(O)-(H or C$_1$-C$_6$ alkyl), -OC(O)N(H or C$_1$-C$_6$ alkyl)$_2$, -OC(O)N(C$_2$-C$_6$ alkylene), -OS(O)-(H or C$_1$-C$_6$ alkyl), -OS(O)$_2$-(H or C$_1$-C$_6$ alkyl), -OS(O)N(H or C$_1$-C$_6$ alkyl)$_2$, -OS(O)N(C$_2$-C$_6$ alkylene), -OS(O)$_2$N(H or C$_1$-C$_6$ alkyl)$_2$, -OS(O)$_2$N(C$_2$-C$_6$ alkylene), -S(H or C$_1$-C$_6$ alkyl), -S(O)(H or C$_1$-C$_6$ alkyl), -S(O)$_2$(H or C$_1$-C$_6$ alkyl), -S(O)N(H or C$_1$-C$_6$ alkyl)$_2$, -S(O)N(C$_2$-C$_6$ alkylene), -S(O)$_2$N(H or C$_1$-C$_6$ alkyl)$_2$, -S(O)$_2$N(C$_2$-C$_6$ alkylene), -N(H or C$_1$-C$_6$ alkyl)$_2$, -N(C$_2$-C$_6$ alkylene), -N(H or C$_1$-C$_6$ alkyl)C(O)-(H or C$_1$-C$_6$ alkyl), -N(H or C$_1$-C$_6$ alkyl)C(O)O(H or C$_1$-C$_6$ alkyl), -N(H or C$_1$-C$_6$ alkyl)C(O)N(H or C$_1$-C$_6$ alkyl)$_2$, -N(H or C$_1$-C$_6$ alkyl)C(O)N(C$_2$-C$_6$ alkylene), -N(H or C$_1$-C$_6$ alkyl)S(O)-(H or C$_1$-C$_6$ alkyl), -N(H or C$_1$-C$_6$ alkyl)S(O)$_2$(H or C$_1$-C$_6$ alkyl), -N(H or C$_1$-C$_6$ alkyl)S(O)N(H or C$_1$-C$_6$ alkyl)$_2$, -N(H or C$_1$-C$_6$ alkyl)S(O)N(C$_2$-C$_6$ alkylene), -N(H or C$_1$-C$_6$ alkyl)S(O)$_2$N(H or C$_1$-C$_6$ alkyl)$_2$, -N(H or C$_1$-C$_6$ alkyl)S(O)$_2$N(C$_2$-C$_6$ alkylene), -C(O)-(H or C$_1$-C$_6$ alkyl), -C(O)O(H or C$_1$-C$_6$ alkyl), -C(O)N(C$_2$-C$_6$ alkylene), -P(H or C$_1$-C$_6$ alkyl)$_2$, -P(C$_2$-C$_6$ alkylene), -P(O)(H or C$_1$-C$_6$ alkyl)$_2$, -P(O)(C$_2$-C$_6$ alkylene), -P(O)$_2$(H or C$_1$-C$_6$ alkyl)$_2$, -P(O)$_2$(C$_2$-C$_6$ alkylene), -P(O)N(H or C$_1$-C$_6$

alkyl)$_2$, -P(O)N(C_2-C_6 alkylene), -P(O)$_2$N(H or C_1-C_6 alkyl)$_2$, -P(O)$_2$N(C_2-C_6 alkylene), -P(O)O(H or C_1-C_6 alkyl), -P(O)$_2$O(H or C_1-C_6 alkyl), -CN, or -NO_2; and

n is 0, 1, 2, 3, or 4.









3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein ring B is a 5- to 10-membered heteroarylene, wherein each hydrogen atom in 5- to 10-membered heteroarylene is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, 5- to 10-membered heteroaryl, -OR^c, -OC(O)R^c, -OC(O)NR^{c}R^d, -OC(=N)NR^{c}R^d, -OS(O)R^c, -OS(O)$_2$R^c, -OS(O)NR^{c}R^d, -OS(O)$_2$NR^{c}R^d, -SR^c, -S(O)R^c, -S(O)$_2$R^c, -S(O)NR^{c}R^d, -S(O)$_2$NR^{c}R^d, -NR^{c}R^d, -NR^{c}C(O)R^d, -N(C(O)R^c)(C(O)R^d), -NR^{c}C(O)OR^d, -NR^{c}C(O)NR^{c}R^d, -NR^{c}C(=N)NR^{c}R^d, -NR^{c}S(O)R^d, -NR^{c}S(O)$_2$R^d, -NR^{c}S(O)NR^{c}R^d, -NR^{c}S(O)$_2$NR^{c}R^d, -C(O)R^c, -C(O)OR^c, -C(O)NR^{c}R^d, -C(=N)NR^{c}R^d, -PR^{c}R^d, -P(O)R^{c}R^d, -P(O)$_2$R^{c}R^d, -P(O)NR^{c}R^d, -P(O)$_2$NR^{c}R^d, -P(O)OR^c, -P(O)$_2$OR^c, -CN, or -NO_2.

4. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein ring B is a 5- to 10-membered heteroarylene selected from the group consisting of




, and , wherein each hydrogen atom in ring B is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3-to 7-membered heterocycloalkyl, C_6-C_{10} aryl, 5- to 10-membered heteroaryl, -OR^c, -OC(O)R^c, -OC(O)NR^{c}R^d, -OC(=N)NR^{c}R^d, -OS(O)R^c, -OS(O)$_2$R^c, -OS(O)NR^{c}R^d, -OS(O)$_2$NR^{c}R^d, -SR^c, -S(O)R^c, -S(O)$_2$R^c, -S(O)NR^{c}R^d, -S(O)$_2$NR^{c}R^d, -NR^{c}R^d, -NR^{c}C(O)R^d, -N(C(O)R^c)(C(O)R^d), -NR^{c}C(O)OR^d, -NR^{c}C(O)NR^{c}R^d, -NR^{c}C(=N)NR^{c}R^d, -NR^{c}S(O)R^d, -NR^{c}S(O)$_2$R^d, -NR^{c}S(O)NR^{c}R^d, -NR^{c}S(O)$_2$NR^{c}R^d, -C(O)R^c, -C(O)OR^c, -C(O)NR^{c}R^d, -C(=N)NR^{c}R^d, -PR^{c}R^d, -P(O)R^{c}R^d, -P(O)$_2$R^{c}R^d, -P(O)NR^{c}R^d, -P(O)$_2$NR^{c}R^d, -P(O)OR^c, -P(O)$_2$OR^c, -CN, or -NO_2.

5. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein ring B is


 ,  ,  ,  ,  ,  ,  , or  .

6. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein












is a 5- to 10-membered heteroarylene, and n is 0, 1, 2, 3, or 4.

7. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein



is a 5- to 10-membered heteroarylene selected from the group consisting of


 ,  ,  ,  ,  ,  ,  ,  , and  .

and n is 0, 1, or 2.


8. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, and n is 0, 1, or 2.

9. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein each R^1, when present, is independently fluoro, chloro, methyl, ethyl, methoxy, ethoxy, -C(O)OR^a, -C(O)NR^aR^b, -CN, or 4-piperidinyl.

10. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein



is a 5- to 10-membered heteroarylene selected from the group consisting of



, and .

11. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein L is an ethylene, propylene, or butylene, wherein each hydrogen atom in ethylene, propylene, and butylene is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, 5- to 10-membered heteroaryl, -OR^a, -$OC(O)R^a$, -$OC(O)NR^aR^b$, -$OS(O)R^a$, -$OS(O)_2R^a$, -SR^a, -$S(O)R^a$, -$S(O)_2R^a$, -$S(O)NR^aR^b$, -$S(O)_2NR^aR^b$, -$OS(O)NR^aR^b$, -$OS(O)_2NR^aR^b$, -NR^aR^b, -$NR^aC(O)R^b$, -$NR^aC(O)OR^b$, -$NR^aC(O)NR^aR^b$, -$NR^aS(O)R^b$, -$NR^aS(O)_2R^b$, -$NR^aS(O)NR^aR^b$, -$NR^aS(O)_2NR^aR^b$, -$C(O)R^a$, -$C(O)OR^a$, -$C(O)NR^aR^b$, -PR^aR^b, -$P(O)R^aR^b$, -$P(O)_2R^aR^b$, -$P(O)NR^aR^b$, -$P(O)_2NR^aR^b$, -$P(O)OR^a$, -$P(O)_2OR^a$, -CN, or -NO_2.

12. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein L is an ethylene, propylene, or butylene, each of which is optionally substituted by a C_1-C_6 alkyl.

13. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein Y is $N(R^5)C(O)$.

14. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt

thereof, wherein R^5, when present, is H or methyl.

15. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein Y is absent.

16. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein Y^1 is O.

17. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein Y^2 is absent.

18. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein m is 1.

19. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein X is $C(R^2)$.

20. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein X^1 is CH or N.

21. The compound of any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, wherein X^1 is $C(R^3)$.

22. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein X^2 is $C(R^4)$.
















23. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R^2, when present, is H.













24. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R^3, when present, is H.













25. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R^4, when present, is H, fluoro, chloro, or methyl.

26. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R^{11} is H.



27. The compound of claim 1, selected from the group consisting of


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,















,

,

,







,




,



















,


,


,

,

,

,

,

,

,

,

,

,

,

,

,

,




















,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

, and



, or a pharmaceutically acceptable salt thereof.

28. A pharmaceutical composition comprising a compound of any one of the preceding claims, and optionally one or more excipients.

29. Use of a compound according to any one of claims 1 to 27 in the manufacture of a medicament for the treatment of disease in a subject.